Precision Oncology: The Future of Personalised Cancer Treatment

Cancer treatment is entering an era in which the question is no longer simply where a cancer began, but what is driving it at a molecular level.

That shift is at the heart of precision oncology. Instead of relying solely on cancer type, stage and other conventional clinical characteristics, precision oncology uses information about a tumour's genes, proteins and other biomarkers to help identify treatments that are more closely matched to its biology. The approach is already part of clinical decision-making for several cancers, although its use is far from universal.

The significance extends beyond a new generation of drugs. Precision oncology is changing the infrastructure around cancer care, from diagnostics and pathology to clinical trials, data interpretation and healthcare delivery.

From treating cancer by organ to understanding its biology

Traditional oncology has largely organised cancer according to where it originates: lung, breast, colon, blood and so on. Precision oncology adds another layer of understanding by examining the molecular alterations that can influence how a tumour behaves and responds to treatment.

Biomarker testing can identify genetic changes or other characteristics that may make a tumour susceptible to a particular targeted treatment or immunotherapy. Some therapies are specifically linked to companion diagnostic tests designed to identify patients most likely to benefit.

This is creating a more nuanced model of cancer treatment: the same tumour type does not necessarily mean the same molecular disease.

The diagnostic engine behind personalised treatment

The expansion of next-generation sequencing (NGS) and comprehensive genomic profiling is one of the key developments supporting this transition.

Rather than examining a single genetic alteration, modern testing can analyse multiple genes and molecular features simultaneously. ESMO has expanded its recommendations for tumour NGS to include additional advanced and rare cancers and the detection of tumour-agnostic alterations where matched therapies are available.

Liquid biopsy is adding another dimension. By analysing circulating tumour DNA (ctDNA) in blood, clinicians and researchers can potentially obtain molecular information without relying exclusively on tissue samples. The FDA's current authorisations include liquid-biopsy companion diagnostics, while noting that a negative plasma result does not necessarily rule out a genomic alteration in the tumour.

That distinction matters. Precision does not simply mean generating more data. It means generating clinically reliable data that can change a treatment decision.

More data creates a new challenge: interpretation

As molecular testing becomes more comprehensive, oncology teams face another problem: how to turn increasingly complex datasets into clinically meaningful decisions.

This is where molecular tumour boards are becoming important. These multidisciplinary groups bring together specialists such as oncologists, pathologists, geneticists and molecular experts to interpret genomic findings and determine whether an alteration is clinically actionable.

In 2025, ESMO published recommendations intended to support more structured implementation of molecular tumour boards, covering areas such as patient selection, data integration, reporting and quality indicators.

Artificial intelligence could further influence this workflow. Research published in Nature Reviews Cancer in 2026 highlighted the convergence of machine learning, clinicogenomic datasets and molecular diagnostics, while also identifying the challenge of translating growing volumes of data into useful clinical insight.

The emerging opportunity, therefore, is not simply more testing. It is building systems capable of interpreting the results responsibly and efficiently.

The next frontier is making precision scalable

Precision oncology still faces significant barriers: testing infrastructure, cost, workforce expertise, data governance, reimbursement and unequal access.

These are not peripheral concerns. They determine whether scientific advances become available beyond highly specialised cancer centres.

The World Health Organization's 2026 resolution on precision medicine explicitly highlighted the need for stronger infrastructure, workforce capacity, governance, affordability and equitable access. Its 2025 analysis of genomic clinical research also found that more than 80% of genomic clinical studies were concentrated in high-income countries, while fewer than 5% were conducted in low- and middle-income countries.

For healthcare organisations, this creates a strategic question: Can precision oncology become a repeatable care model rather than a capability available only in pockets of the system?

That will require collaboration across hospitals, diagnostic laboratories, pharmaceutical companies, technology providers, researchers, regulators and payers.

A future built around continuously evolving cancer data

Cancer itself evolves. Treatment can create selective pressure, resistance can emerge and the molecular profile of a tumour can change over time. This makes the future of precision oncology less about finding one perfect treatment and more about creating a continuous feedback loop between diagnosis, molecular data, treatment and monitoring.

Liquid biopsy, advanced imaging, genomic profiling and AI-assisted analysis could increasingly contribute to that loop. At the same time, the industry will need stronger evidence, careful regulation and responsible data governance.

The promise of precision oncology, then, is not simply that every patient will receive a completely different drug. Its deeper significance is that cancer care is becoming increasingly capable of asking a more precise question: What is this particular disease doing, and what evidence can guide the next decision?

That shift could reshape the future of personalised cancer treatment. But turning molecular precision into meaningful patient outcomes will ultimately depend on something broader than technology: the ability of healthcare systems to make innovation clinically useful, economically sustainable and accessible to the people who need it.